5Y News | Syneron Bio Closes $150 Million Series B Round
Syneron Bio today announced the completion of its Series B funding round.
Syneron Bio, a leading company in AI-driven macrocyclic peptide drug discovery, today announced the completion of its Series B financing. The round was led by an international biotech fund, with Decheng Capital and CDH Investments' VGC platform as co-leads. Follow-on investors included a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), Dymon Asia Ventures (an independent wholly-owned subsidiary of Temasek), Qiming Venture Partners, BioTrack Capital, and a prominent industry-focused investment firm. Existing shareholders including AstraZeneca, LAV (Lilly Asia Ventures), Sinovation Ventures, 5Y Capital, Hillhouse (GL Ventures), Biotech Development Fund, and Lenovo Capital and Incubator Group also continued their support.
The proceeds will be primarily directed toward advancing the intelligent iteration of the company's proprietary macrocyclic peptide discovery platform, Synova™, and accelerating the progression of its diversified pipeline of innovative drug candidates into clinical stages.
Dr. Xiao Zhang, founder and CEO of Syneron Bio, stated: "We are deeply honored to receive the support and recognition from this distinguished group of leading global healthcare investment funds, technology venture capital firms, multinational corporations, and top-tier sovereign wealth funds in this financing round. The completion of this financing will further strengthen our capital reserves, enabling us to accelerate the development of multiple core pipelines in oncology, autoimmune diseases, metabolic disorders, and rare diseases, ultimately benefiting patients worldwide. At the same time, our high-throughput, AI-driven Synova™ platform will undergo accelerated upgrades and expansion, significantly enhancing the efficiency and success rate of macrocyclic peptide drug R&D. We look forward to continuing to deliver innovative therapies to patients globally and addressing major unmet clinical needs, supported by our capital and industry partners."
Xutian Jing, Partner at 5Y Capital, commented: "AI-powered technology platforms are driving the development of novel peptides with unprecedented properties, opening up entirely new frontiers in pharmaceutical development with immeasurable future market value. We remain firmly optimistic about the application potential of innovative technologies in the life sciences sector."
5Y Capital seeks out, supports, and inspires founders who dare to stand alone, providing them with support from spiritual encouragement to full operational backing.
We believe that if the world begins to believe in the "crazy" ones, things will get interesting.
BEIJING · SHANGHAI · SHENZHEN · HONG KONG
